Pulmonary arterial hypertension (PAH) patients referred for transplant typically have an inadequate response to guideline-directed therapies, are at intermediate-to-high risk of death (with 1-year mortality exceeding 10%), or have conditions like pulmonary capillary hemangiomatosis (PCH) or pulmonar

In patients with pulmonary hypertension, an elevated pulmonary vascular resistance (PVR) of 3.0 Wood units (WU) or more has been known to be associated with poor clinical prognosis.¹ In a recent study published in The Lancet